In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1743-1749

  Du, Xiaohui ^a,b   Jin, Runsen ^b,c   Ning, Ning ^a,b   Li, Li ^b   Wang, Quansheng ^b   Liang, Wentao ^b   Liu, Juchao ^b   Xu, Yingxin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adoptive cellular immunotherapy; Antitumor activity; Bispecific antibody; CIK cells; CTL cells; Gastric cancer model; In vivo distribution

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSPLANTATION; CELLULAR DISTRIBUTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; FEMALE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STOMACH CANCER; THERAPY EFFECT; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; ORGANIC CHEMICALS; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84866443296     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2013     Document Type: Article

References (40)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Kim HM, Kang JS, Lim J, et al: Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res 32: 781-787, 2009.
3. + T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 17: 5343-5352, 2011.
4. Marcus A and Eshhar Z: Tumor-specific allogeneic cells for cancer therapy. Expert Opin Biol Ther 11: 1551-1554, 2011.
5. June CH: Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476, 2007. (Pubitemid 46871329)
6. Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683, 2011.
7. Zhong JH, Ma L, Wu LC, et al: Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract 66: 21-27, 2012.
8. Toh U, Fujii T, Mishima M, et al: Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer. Gan To Kagaku Ryoho 34: 1931-1933, 2007 (In Japanese).
9. Linn YC and Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010: 435745, 2010.
10. Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2: 363-368, 2011.
11. Ma Y, Zhang Z, Tang L, et al: Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14: 483-493, 2012.
12. Wright SE, Rewers-Felkins KA, Quinlin IS, et al: Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 35: 196-204, 2012.
13. Hickey MJ, Malone CC, Erickson KE, et al: Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. Am J Transl Res 4: 114-126, 2012.
14. Yang M, Baranov E, Jiang P, et al: Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 97: 1206-1211, 2000. (Pubitemid 30080837)
15. Chishima T, Miyagi Y, Wang X, et al: Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 57: 2042-2047, 1997. (Pubitemid 27209739)
16. Heim R, Cubitt AB and Tsien RY: Improved green fluorescence. Nature 373: 663-664, 1995.
17. Kaneko K, Yano M, Tsujinaka T, et al: Establishment of a visible peritoneal micrometastatic model from a gastric adenocarcinoma cell line by green fluorescent protein. Int J Oncol 16: 893-898, 2000.
18. Kaneko K, Yano M, Yamano T, et al: Detection of peritoneal micrometastases of gastric carcinoma with green fluorescent protein and carcinoembryonic antigen promoter. Cancer Res 61: 5570-5574, 2001. (Pubitemid 32694944)
19. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
20. Linn YC, Lau LC and Hui KM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116: 78-86, 2002. (Pubitemid 34122063)
21. Lopez RD, Waller EK, Lu PH and Negrin RS: CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 49: 629-640, 2001. (Pubitemid 32656624)
22. Niam M, Linn YC, Fook Chong S, et al: Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol 39: 897-903, 2011.
23. Hazelrigg MR, Hirsch JI and Merchant RE: Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J Neurooncol 60: 143-150, 2002. (Pubitemid 35291237)
24. Skitzki J, Craig RA, Okuyama R, et al: Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 64: 2183-2191, 2004. (Pubitemid 38339471)
25. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH and Negrin RS: Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101: 640-648, 2003. (Pubitemid 36077588)
26. Nishimura R, Baker J, Beilhack A, et al: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112: 2563-2574, 2008.
27. Brandau S and Bohle A: Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol 39: 518-524, 2001. (Pubitemid 32678965)
28. + cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients. Int J Oncol 19: 561-566, 2001.
29. Nagaraj S, Ziske C and Schmidt-Wolf IG: Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther 2: 12, 2004.
30. Marten A, Renoth S, von Lilienfeld-Toal M, et al: Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86: 1029-1037, 2001. (Pubitemid 33031868)
31. Ziske C, Marten A, Schottker B, et al: Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. Mol Ther 3: 54-60, 2001. (Pubitemid 32509805)
32. van Spriel AB, van Ojik HH and van De Winkel JG: Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21: 391-397, 2000.
33. + natural-killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother 49: 441-448, 2000.
34. Lutterbuese R, Raum T, Kischel R, et al: Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 32: 341-352, 2009.
35. + cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol 28: 70-76, 2007.
36. + T cell functions and generation of cytotoxic T lymphocytes. J Biomed Biotechnol 2010: 605483, 2010.
37. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173, 2002.
38. + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24: 5060-5069, 2006.
39. +lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13: 1857-1867, 2007.
40. Yamaguchi Y, Ohshita A, Hironaka K, et al: Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells. Oncol Rep 16: 165-169, 2006.